We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 19, 2020

Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration of Mitomycin C for High-Grade Non–Muscle Invasive Bladder Cancer After BCG Failure

Urologic Oncology: Seminars & Original Investigations

 

Additional Info

Disclosure statements are available on the authors' profiles:

Urologic Oncology: Seminars & Original Investigations
Sequential Administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of Mitomycin C (MMC) for the Treatment of High-Grade Nonmuscle Invasive Bladder Cancer After BCG Failure
Urol. Oncol 2020 Jul 22;[EPub Ahead of Print], T Juvet, A Mari, K Lajkosz, CJ Wallis, C Kuk, A Erlich, L Krimus, NE Fleshner, GS Kulkarni, AR Zlotta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading